Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Class A and Class B Common Stock Class A and Class B Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Shares, beginning of period (in shares) at Jan. 31, 2021	167,058,113
Balance, beginning of period at Jan. 31, 2021	$ 621,139
Increase (Decrease) in Temporary Equity [Roll Forward]
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)	(167,058,113)
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	$ (621,139)
Shares, end of period (in shares) at Jan. 31, 2022	0
Balance, end of period at Jan. 31, 2022	$ 0
Shares, beginning of period (in shares) at Jan. 31, 2021		39,242,316
Balance, beginning of period at Jan. 31, 2021	(320,536)	$ 2	$ 29,869	$ 165	$ (350,572)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)		169,787,200
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	621,139	$ 10	621,129
Issuance of common stock upon initial public offering and private placements, net of underwriting discounts and commissions (in shares)		41,678,568
Issuance of common stock upon initial public offering and private placements, net of underwriting discounts and commissions	1,380,960	$ 4	1,380,956
Issuance of common stock upon exercise of options (in shares)		9,793,331
Issuance of common stock upon exercise of options	14,621	$ 10	14,611
Issuance of common stock upon exercise of warrants (in shares)		940,953
Vesting of restricted stock units (in shares)		15,218
Issuance of common stock under employee stock purchase plan (in shares)		381,716
Issuance of common stock under employee stock purchase plan	11,356		11,356
Issuance of restricted stock for services provided (in shares)		20,000
Issuance of restricted stock for services provided	500		500
Vesting of early exercised options	572		572
Issuance of common stock and awards assumed in connection with acquisition (in shares)		7,277,214
Issuance of common stock and awards assumed in connection with acquisition	120,320	$ 1	120,319
Issuance of restricted stock awards (in shares)		1,315,099
Stock-based compensation	92,668		92,668
Foreign currency translation adjustments	289			289
Shares, end of period (in shares) at Jan. 31, 2022		270,451,615
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	0
Net loss	(271,101)
Balance, end of period at Jan. 31, 2022	$ 1,650,788	$ 27	2,271,980	454	(621,673)
Shares, end of period (in shares) at Jan. 31, 2023	0
Balance, end of period at Jan. 31, 2023	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)		7,650,525
Issuance of common stock upon exercise of options	17,335	$ 1	17,334
Vesting of restricted stock units (in shares)		1,303,854
Issuance of common stock under employee stock purchase plan (in shares)		1,335,183
Issuance of common stock under employee stock purchase plan	19,159		19,159
Cancellation of holdback shares		(9,551)
Vesting of early exercised options	103		103
Issuance of common stock and awards assumed in connection with acquisition (in shares)		6,032,231
Issuance of common stock and awards assumed in connection with acquisition	186,333	$ 1	186,332
Stock-based compensation	168,486		168,486
Foreign currency translation adjustments	0
Shares, end of period (in shares) at Jan. 31, 2023		286,763,857
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	(6,821)			(6,821)
Net loss	(378,678)				(378,678)
Balance, end of period at Jan. 31, 2023	$ 1,656,705	$ 29	2,663,394	(6,367)	(1,000,351)
Shares, end of period (in shares) at Jan. 31, 2024	0
Balance, end of period at Jan. 31, 2024	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)		10,298,114
Issuance of common stock upon exercise of options	28,318	$ 1	28,317
Vesting of restricted stock units (in shares)		6,021,877
Issuance of common stock under employee stock purchase plan (in shares)		1,607,874
Issuance of common stock under employee stock purchase plan	19,147		19,147
Vesting of early exercised options	186		186
Stock-based compensation	223,563		223,563
Foreign currency translation adjustments	0
Shares, end of period (in shares) at Jan. 31, 2024		304,691,722
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive loss	4,817			4,817
Net loss	(338,693)				(338,693)
Balance, end of period at Jan. 31, 2024	$ 1,594,043	$ 30	$ 2,934,607	$ (1,550)	$ (1,339,044)